Lung cancer immunotherapy: progress, pitfalls, and promises

Area of Science:

• Oncology
• Immunology
• Nanomedicine

Background:

• Lung cancer remains a leading global cause of mortality, with conventional treatments often leading to resistance and relapse.
• Immunotherapy is revolutionizing cancer care due to its safety, durable responses, and broad applicability.
• Tumor-specific vaccination and adoptive cell therapies are emerging as key strategies in lung cancer treatment.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in lung cancer immunotherapy.
• To discuss adoptive cell therapies (CAR T, TCR, TIL) and their clinical applications in lung cancer.
• To explore the role of nanomedicine and combination therapies in enhancing lung cancer immunotherapy.

Main Methods:

• Review of recent clinical trials and scientific literature on lung cancer immunotherapy.
• Analysis of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade efficacy.
• Examination of therapeutic cancer vaccines, adoptive cell therapies, and nanomedicine applications.

Main Results:

• Significant and sustained responses observed in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors, particularly those without targetable driver alterations.
• Evidence suggests a link between the loss of anti-tumor immunity and lung tumor evolution.
• Combination of therapeutic cancer vaccines with immune checkpoint inhibitors demonstrates enhanced therapeutic effects.

Conclusions:

• Immunotherapy, including checkpoint inhibitors and vaccines, is a promising frontier for treating both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
• Nanomedicine and combination strategies hold potential for improving immunotherapy efficacy.
• Ongoing research and clinical trials are crucial for overcoming obstacles and advancing lung cancer immunotherapy.